Ascendis Pharma (ASND) Company Report

Analyst Coverage

Research analysts who have asked questions during Ascendis Pharma earnings calls.

David Lebowitz

Citigroup Inc.

5 questions for ASND

Also covers: ALNY, ARWR, BPMC +11 more

Gavin Clark-Gartner

Evercore ISI

5 questions for ASND

Also covers: ACRS, ARGX, CMPS +11 more

Jessica Fye

JPMorgan Chase & Co.

5 questions for ASND

Also covers: ALKS, ALNY, AMRN +23 more

Tazeen Ahmad

Bank of America

5 questions for ASND

Also covers: ACAD, ALNY, APLS +20 more

Derek Archila

Wells Fargo

4 questions for ASND

Also covers: APLS, ARGX, ARVN +9 more

Leland Gershell

Oppenheimer & Co. Inc.

4 questions for ASND

Also covers: ARGX, CAPR, CASI +13 more

Li Wang Watsek

Cantor Fitzgerald

4 questions for ASND

Also covers: AFMD, ALXO, ARVN +7 more

Paul Choi

Goldman Sachs

4 questions for ASND

Also covers: AMRN, ARVN, BBIO +12 more

Joseph Schwartz

Oppenheimer

3 questions for ASND

Also covers: AUPH, BMRN, CRNX +14 more

Luca Issi

RBC Capital Markets

3 questions for ASND

Also covers: ADVM, ALLO, ALNY +12 more

Yaron Werber

TD Cowen

3 questions for ASND

Also covers: ALEC, AMGN, ARGX +14 more

Alexander Thompson

Stifel

2 questions for ASND

Also covers: ACRS, ARGX, CRNX +4 more

Dingding Shi

Jefferies

2 questions for ASND

Also covers: ADCT, AUTL, INCY +6 more

Ellie Merle

UBS Group AG

2 questions for ASND

Also covers: ALNY, ALT, ARVN +12 more

Kelly Shi

Jefferies

2 questions for ASND

Also covers: ADCT, AGEN, ALDX +17 more

Vikram Purohit

Morgan Stanley

2 questions for ASND

Also covers: ABSI, ARGX, ARQT +11 more

Alex Thompson

Stifel Financial Corp.

1 question for ASND

Also covers: ARGX, CRNX, KYMR +1 more

Daniel Bronder

Cantor Fitzgerald

1 question for ASND

Also covers: CRIS

Eliana Merle

UBS

1 question for ASND

Also covers: ALNY, APLS, ARVN +17 more

Joori Park

Leerink Partners

1 question for ASND

Also covers: PTGX

Jose Lora

Jefferies

1 question for ASND

Also covers: HRTX

Kyuwon Choi

Goldman Sachs

1 question for ASND

Also covers: AMRN, BHVN, CYTK +9 more

Maxwell Skor

H.C. Wainwright & Co.

1 question for ASND

Also covers: AVIR, CRNX, CYTK +4 more

Simona Stan

Wells Fargo

1 question for ASND

Yun Zhong

Wedbush Securities

1 question for ASND

Also covers: MNKD, MRKR, PASG +2 more

Latest news

Recent press releases and 8-K filings for ASND.

Ascendis Pharma Provides Business Update at J.P. Morgan Healthcare Conference

ASND

Revenue Acceleration/Inflection

Guidance Update

Share Buyback

Ascendis Pharma reported strong financial performance with Q4 product revenue of approximately EUR 240 million and full-year revenue of approximately EUR 683 million.
The company projects significant future growth, targeting over EUR 5 billion in revenue by 2030, primarily driven by Yorvipath and Skytrofa.
Key upcoming milestones include the PDUFA date for TransCon CNP in February and a plan to buy back at least $120 million in shares this year.
Ascendis Pharma anticipates an operating cash flow of at least EUR 500 million and is expanding its European presence for Yorvipath with 10+ new countries expected in 2026.

3 days ago

Transcript

Highlights from the 44th J.P. Morgan Healthcare Conference

ASND

Guidance Update

Product Launch

New Projects/Investments

Ascendis Pharma (ASND) reported total full-year product revenue of $720 million for 2025, with Yorvipath contributing $477 million and SKYTROFA $206 million. The company anticipates TransCon CNP approval in Q1 2026 and plans a $120 million share buyback. Global peak sales expectations for Yorvipath are $5-$8 billion.
CRISPR Therapeutics highlighted its approved product Casgevy with multi-billion-dollar revenue potential and pipeline progress, including CTX310 for hypercholesterolemia, CTX611 (Factor XI siRNA) in Phase 2, and a 70% complete response rate for Zugocel (CAR-T) in oncology.
An unnamed company (Speaker 1) reported total net product revenue of $1.86 billion for FY 2025, including $899 million from Elevidys and $966 million from PMOs. The company ended 2025 with $954 million in cash and expects to be cash flow positive throughout the decade, with biomarker data for FSHD and DM1 programs expected by the end of Q1 2026.

3 days ago

Transcript

Companies Present Financial and Product Updates at J.P. Morgan Healthcare Conference

ASND

Revenue Acceleration/Inflection

Product Launch

Share Buyback

Ascendis Pharma reported Q4 product revenue of approximately EUR 240 million and full-year 2025 product revenue of about EUR 683 million, primarily from Yorvipath and Skytrofa, and aims for over EUR 5 billion in revenue by 2030. The company also plans to buy back at least $120 million in shares.
CRISPR Therapeutics announced that its approved product, Casgevy, has achieved over $100 million in revenue and shows strong momentum, with the company also highlighting CTX310 as a potential multi-billion-dollar opportunity in hypercholesterolemia.
Sarepta Therapeutics reported full-year 2025 total net product revenue of $1.86 billion, with Elevidys contributing $899 million (9% growth) and PMOs $966 million, ending the year with $954 million in cash and cash equivalents.

3 days ago

Transcript

Ascendis Pharma Reports 2025 Product Revenue and Outlines Vision 2030 Goals

ASND

Earnings

Guidance Update

Product Launch

Ascendis Pharma reported Q4 2025 product revenue of approximately €240 million and FY 2025 product revenue of approximately €683 million.
The company aims to achieve over €5 billion in annual revenue by 2030 as part of its Vision 2030 strategy, focusing on worldwide commercialization of its Endocrinology Rare Disease medicines.
Key product YORVIPATH® (TransCon PTH) generated approximately €477 million in FY 2025 revenue and is expanding commercially in over 30 countries.
SKYTROFA® (TransCon hGH) is approved for pediatric and adult growth hormone deficiency, with ongoing label and geographic expansion plans.
TransCon® CNP has an FDA PDUFA date of February 28, 2026, for achondroplasia, with an EU MAA decision anticipated in Q4 2026.

3 days ago

Presentation

Ascendis Pharma A/S Provides Business and Strategic Roadmap Update and Authorizes Share Repurchase Program

ASND

Guidance Update

New Projects/Investments

Share Buyback

Ascendis Pharma A/S provided a business and strategic roadmap update on January 9, 2026, outlining planned 2026 key corporate milestones.
Key regulatory updates include a U.S. PDUFA goal date of February 28, 2026, for TransCon CNP in pediatric achondroplasia, and an anticipated Q1 2026 approval decision from China's NMPA for TransCon hGH in pediatric growth hormone deficiency.
The company announced positive Week 52 topline results from the Phase 2 COACH Trial for TransCon CNP + TransCon hGH combination therapy on January 8, 2026, demonstrating improvements in annualized growth velocity and body proportionality.
The Board of Directors authorized a $120 million Share Repurchase Program.

4 days ago

6-K

Ascendis Pharma Provides 2025 Financial Outlook and 2026 Strategic Milestones

ASND

Earnings

Guidance Update

Share Buyback

Ascendis Pharma expects total full-year 2025 revenue of ~€720 million, with YORVIPATH contributing ~€477 million and SKYTROFA ~€206 million. The company also anticipates a full-year 2025 gross margin of ~87% and operating expenses of ~€762 million.
The unaudited preliminary cash balance as of December 31, 2025, is ~€616 million, and the company expects ~€500 million in operating cash flow for 2026.
A $120 million share repurchase program is planned for 2026.
Key regulatory milestones include a U.S. PDUFA goal date of February 28, 2026, for TransCon CNP, anticipated approval for TransCon hGH in China in the first quarter of 2026, and YORVIPATH's MAA approval in Japan in August 2025.

6 days ago

Press Release

Ascendis Pharma A/S Announces Positive Topline Phase 2 COACH Trial Results for Combination Therapy in Achondroplasia

ASND

New Projects/Investments

Ascendis Pharma A/S announced positive topline results from Week 52 of the COACH Phase 2 clinical trial for combination therapy with TransCon CNP and TransCon hGH in children with achondroplasia on January 8, 2026.
The combination therapy demonstrated durable growth without compromising safety or tolerability, showing benefits beyond linear growth with improvements in body proportionality and arm span.
For the TransCon CNP treatment-naïve cohort, mean annualized growth velocity (AGV) was 8.80 cm/year, with an improvement in mean ACH height Z-score of +1.02 over 52 weeks, indicating a tripling of efficacy compared to TransCon CNP monotherapy.
TransCon CNP is under Priority Review by the U.S. FDA with a PDUFA target action date of February 28, 2026, and Ascendis submitted a protocol for a Phase 3 trial of the combination therapy in pediatric achondroplasia in Q4 2025.

7 days ago

6-K

Ascendis Pharma Reports Positive Phase 2 Coach Trial Data

ASND

New Projects/Investments

Ascendis Pharma announced positive topline Week 52 data from its Phase 2 Coach Trial, investigating the combination of TransCon hGH with TransCon CNP for children with achondroplasia.
The combination therapy demonstrated significant efficacy, with treatment-naive children achieving an annualized growth velocity of 8.8 cm/year and an improvement in height SDS of +1.02, substantially exceeding monotherapy results.
Beyond linear growth, the trial showed statistically significant improvements in body proportionality and arm span.
The trial reported 100% patient retention over one year, with a safety and tolerability profile consistent with the individual products.
The company plans a Phase 3 trial with two arms (monotherapy and combination therapy) to further evaluate the treatment, with linear growth as the primary endpoint and an emphasis on benefits beyond linear growth.

7 days ago

Transcript

Ascendis Pharma Reports Positive Phase II Coach Trial Data for TransCon CNP and TransCon hGH Combination

ASND

New Projects/Investments

Product Launch

Ascendis Pharma announced positive top-line Week 52 data from its Phase II Coach Trial, which investigated the addition of TransCon hGH to TransCon CNP monotherapy in children with achondroplasia.
The combination therapy demonstrated an annualized growth velocity of 8.8 centimeters per year in treatment-naive children and 8.4 centimeters per year in TransCon CNP-experienced children, significantly exceeding historical benchmarks.
Beyond linear growth, the trial showed improvements in body proportionality and a statistically significant increase in arm span.
Ascendis Pharma is preparing for a Phase 3 trial for the combination therapy, with the pricing structure expected to be the sum of the two individual drugs.
The company is also awaiting FDA approval for TransCon CNP as a monotherapy in the U.S., with confidence that it will occur in the near future.

7 days ago

Transcript

Ascendis Pharma Announces Phase 2 Coach Trial Topline Week 52 Data

ASND

Ascendis Pharma announced positive top-line Week 52 data from its Phase 2 Coach Trial, evaluating the combination of TransCon CNP and TransCon hGH in children with achondroplasia.
The combination therapy demonstrated significant efficacy, with TransCon CNP treatment-naive children achieving an annualized growth velocity of 8.8 cm/year and a +1.02 improvement in achondroplasia-specific height Z-score.
For TransCon CNP-treated experienced children, the combination resulted in an annualized growth velocity of 8.42 cm/year and a +0.86 improvement in achondroplasia-specific height Z-score.
The trial showed an excellent safety profile, with adverse events generally mild, no symptomatic hypotension, and bone age remaining consistent with chronological age.
Beyond linear growth, the combination also improved body proportionality and significantly increased arm span. Ascendis Pharma is preparing for a Phase 3 trial for the combination therapy.